TransCode Therapeutics, Inc. (RNAZ)
| Market Cap | 33.99M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 11.97M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 153,366 |
| Open | 2.96 |
| Previous Close | 2.98 |
| Day's Range | 2.82 - 2.98 |
| 52-Week Range | 2.35 - 7.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | Nov 15, 2021 |
About RNAZ
TransCode Therapeutics is an emerging RNA oncology company, created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. Our strategy seeks to overcome RNA-based therapeutics delivery challenges by repurposing a particle used extensively in humans for imaging purposes to deliver synthetic RNA molecules (called oligonucleotides) to cancer cells. We have created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving pat...
Financial Performance
Financial StatementsNews
TransCode Therapeutics Appoints Zdravka Medarova, Ph.D., as Chief Technology Officer
BOSTON--(BUSINESS WIRE)--TransCode Therapeutics, Inc. (TransCode) (Nasdaq: RNAZ), an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and ef...
RNAZ Stock Alert: The Breast Cancer Study News Sending TransCode Therapeutics Soaring Today
TransCode Therapeutics (RNAZ) stock is rocketing higher on Thursday as investors react to positive news from a breast cancer study. The post RNAZ Stock Alert: The Breast Cancer Study News Sending TransC...
5 Penny Stocks to Watch That Exploded Today, What You Need to Know
These penny stocks exploded during today's trading session, are they worth watching or not? The post 5 Penny Stocks to Watch That Exploded Today, What You Need to Know appeared first on Penny Stocks to ...
Here's why TransCode Therapeutics stock is up about 65% on Thursday
Shares of TransCode Therapeutics Inc (NASDAQ: RNAZ) climbed by 65% on Thursday morning as the oncology company said in its press release that the preclinical research supporting its lead candidate, TTX-...
Why Are TransCode Therapeutics Shares Shooting Higher On Thursday?
TransCode Therapeutics Inc (NASDAQ: RNAZ) is trading higher after preclinical research supporting its lead candidate, TTX-MC138, was published in Cancer Nanotechnology. Related: TransCode Therapeutic...
TransCode Therapeutics Announces Publication in Cancer Nanotechnology of Preclinical Data Supporting Therapeutic Pote...
BOSTON--(BUSINESS WIRE)--TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective deli...
TransCode Therapeutics Reports Business Progress and Second Quarter 2021 Financial Results
BOSTON--(BUSINESS WIRE)--TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an emerging RNA oncology company, created on the belief that cancer can be defeated through the intelligent design and effective del...
TransCode Therapeutics Secures NIH Funding To Support Its Lead Program Development
TransCode Therapeutics Inc (NASDAQ: RNAZ) has received a Fast-Track Small Business Innovation Research (SBIR) grant from the NIH to support developing TTX-MC138. TTX-MC138 is TransCode's lead therapeuti...
TransCode Therapeutics Awarded Funding from National Institutes of Health (NIH) to Support Clinical Evaluation of TTX...
BOSTON--(BUSINESS WIRE)--TransCode Therapeutics, Inc. (Nasdaq: RNAZ), a platform company solving the challenge of RNA delivery in oncology, today announced that it has been awarded a Fast-Track Small Bu...
TransCode Therapeutics, Inc. Announces Closing of Initial Public Offering, Including Full Exercise of Underwriters' O...
BOSTON--(BUSINESS WIRE)--TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), an emerging RNA oncology company created on the belief that cancer can be defeated through the intell...
TransCode Therapeutics, Inc. Announces Pricing of Initial Public Offering
BOSTON--(BUSINESS WIRE)--TransCode Therapeutics IPO Pricing Release
Oncology biotech Transcode Therapeutics files for a $30 million IPO
Transcode Therapeutics, a preclinical biotech developing RNA-based therapies for cancer, filed on Friday with the SEC to raise up to $30 million in an initial public offering.
TransCode Therapeutics IPO Registration Document (S-1)
TransCode Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.